Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth in Texas
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in Texas
| Provider | Medicare | Services |
|---|---|---|
| Chilcoat, Jill MD | $122.12 | 44 |
| Thomas, Christopher M.D. | $380.86 | 36 |
| Tharp, David MD | $425.08 | 36 |
| Johnston, David M.D. | $399.53 | 33 |
| Pfeifer, F. MD | $422.15 | 32 |
| Saravanan, Arthy M.D. | $400.50 | 30 |
| Michell, Michael MD | $360.00 | 29 |
| Boyce, Whitney MD | $385.11 | 26 |
| Jekot, Elizabeth MD | $119.32 | 25 |
Texas Pricing in Context
In Texas, CPT code 19081 (Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth) carries an average Medicare payment of $192.52 — 9% below the national benchmark of $210.47. 448 providers across the state submitted claims for this procedure in 2023, performing 2.8K total services. Individual payments in TX ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in Texas is $1,758.03, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Texas sits below the national Medicare average, commercial rates in the state may also run lower than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Skin/Integumentary Surgery procedures, the estimated commercial insurance price in Texas lands near $568.65, with self-pay cash prices typically around $668.89. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth cost in Texas?
The average Medicare payment for Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth in Texas is $192.52, which is 9% below the national average of $210.47. Providers in TX typically bill $1,758.03 for this procedure.
What does Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth cost with insurance in Texas?
With commercial insurance in Texas, Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth costs an estimated $568.65. Without insurance, the estimated cash price is $668.89. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth in Texas?
448 providers in Texas billed Medicare for Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth in 2023, performing 2.8K total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth cheaper in Texas than the national average?
Yes — Biopsy Of Breast And Placement Of Locating Device Using X-Ray With Needle, First Growth costs 9% below the national average in Texas. The state average Medicare payment is $192.52 compared to $210.47 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.